BioCentury
ARTICLE | Finance

Extending Exonics

How TCG is helping gene editing play Exonics transition from virtual to physical

November 11, 2017 12:26 AM UTC

After courting investment offers from several undisclosed VCs and pharmas, gene editing company Exonics Therapeutics Inc. signed on to a $40 million series A from The Column Group because of the VC’s hands-on approach to helping newcos transition from virtual to physical operations.

Exonics debuted in February with a $5 million seed round from CureDuchenne Ventures and CRISPR technology spun out of the lab of scientific founder and Chief Scientific Adviser Eric Olson. Olson is a professor at University of Texas Southwestern Medical Center...

BCIQ Company Profiles

Exonics Therapeutics Inc.